Form 4: 10x Genomics Director Sells Shares Under 10b5-1 Plan
Insider Transaction Report
10x Genomics Director Sarah A. Teichmann sold 7,579 shares of Class A Common Stock at $19.41 per share under a pre-arranged Rule 10b5-1 trading plan.
Summary
- Sarah A. Teichmann, a Director at 10x Genomics, Inc. (TXG), disposed of 7,579 shares of Class A Common Stock.
- The transaction occurred on February 25, 2026, with shares sold at a price of $19.41 each.
- The sale was executed pursuant to a Rule 10b5-1 trading plan, which was adopted on November 26, 2025.
- Following this transaction, Sarah A. Teichmann beneficially owns 26,780 shares of Class A Common Stock directly.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral event. The sale is a pre-planned transaction under a Rule 10b5-1 plan, which is a routine personal financial management activity for insiders and does not typically convey new information about the company's operational or financial health.
Positives
- The sale was conducted under a Rule 10b5-1 trading plan, adopted on November 26, 2025, which demonstrates a commitment to compliance and pre-planned personal financial management, reducing the perception of opportunistic insider trading.
Negatives
- A director selling shares, even under a pre-arranged plan, can sometimes be perceived by the market as a lack of confidence, although the 10b5-1 plan mitigates this concern.
Future Outlook
The filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.
Industry Context
StockSavvy.ai notes that insider sales executed under Rule 10b5-1 plans are a common practice for corporate executives and directors to manage personal liquidity and diversification without being accused of trading on material non-public information. Such transactions are generally viewed as routine and do not typically reflect a change in the company's fundamental prospects or a negative signal about its future, unlike unscheduled insider sales.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Insider Trading Policy Compliance | The reporting person utilized a Rule 10b5-1 trading plan, adopted on November 26, 2025, to execute the sale of shares. This plan allows insiders to pre-arrange trades to avoid accusations of trading on material non-public information. | 11/26/2025 | Enhances transparency and compliance with insider trading regulations, demonstrating a commitment to ethical conduct and reducing potential legal risks for the insider and the company. |
| Delegation of Authority | Sarah A. Teichmann executed a Power of Attorney on February 27, 2026, appointing Randy Wu and James Bryant as attorneys-in-fact to prepare and file Forms 3, 4, and 5 with the SEC on her behalf. | 02/27/2026 | Streamlines the process for fulfilling SEC reporting obligations for the director, ensuring timely and accurate filings while maintaining compliance with Section 16 of the Securities Exchange Act of 1934. |
Stakeholder Impact
- Shareholders: The impact on shareholders is generally minimal as this is a routine, pre-planned insider transaction. It does not typically signal a change in the company's fundamentals.
- Reporting Person (Sarah A. Teichmann): The transaction results in a reduction of her direct beneficial ownership in 10x Genomics, Inc. and provides personal liquidity.
Key Dates
| Date | Description |
|---|---|
| 11/26/2025 | Date the Rule 10b5-1 trading plan was adopted by Sarah A. Teichmann. |
| 02/25/2026 | Date of the reported transaction where Sarah A. Teichmann sold Class A Common Stock. |
| 02/27/2026 | Date the Form 4 was signed by Randy Wu, as Attorney-in-Fact for Sarah A. Teichmann, and the Power of Attorney was executed. |
Recommendation
holdThe sale by a director under a pre-arranged Rule 10b5-1 plan is a standard practice for personal financial management and does not typically signal a change in the company's fundamental prospects. Investors should maintain their current position based on broader company performance and market conditions rather than this specific transaction, which is not indicative of new material information.
Keywords
10x Genomics, TXG, insider trading, Form 4, Rule 10b5-1, stock sale, director, Sarah Teichmann
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.